High-resolution	B-PROCESS
mass	I-PROCESS
spectrometry	I-PROCESS
detected	O
altered	O
purine	B-PROCESS
metabolism	I-PROCESS
in	O
gout	B-DISEASE
patients	O
with	O
hyperuricemia.	B-DISEASE

The	O
metabolomic	B-PROCESS
study	I-PROCESS
revealed	O
increased	O
4-hydroxyphenylpyruvate	B-CHEMICAL
levels	O
in	O
tyrosinemia	B-DISEASE
patients	O
with	O
enzyme	B-PROCESS
deficiency.	I-PROCESS

Plasma	O
analysis	O
showed	O
decreased	O
carnitine	B-CHEMICAL
availability	O
in	O
patients	O
with	O
fatty	B-PROCESS
acid	I-PROCESS
oxidation	I-PROCESS
disorders.	O

The	O
targeted	O
screening	O
identified	O
elevated	O
methylcitrate	B-CHEMICAL
concentrations	O
in	O
patients	O
with	O
propionyl-CoA	B-CHEMICAL
carboxylase	I-CHEMICAL
deficiency.	O

Urine	O
analysis	O
revealed	O
increased	O
orotic	B-CHEMICAL
acid	I-CHEMICAL
levels	O
in	O
patients	O
with	O
urea	B-PROCESS
cycle	I-PROCESS
enzyme	I-PROCESS
disorders.	O

The	O
comprehensive	O
profiling	O
detected	O
altered	O
polyamine	B-PROCESS
metabolism	I-PROCESS
in	O
cancer	B-DISEASE
patients	O
with	O
enhanced	O
cell	B-PROCESS
proliferation.	I-PROCESS

Systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
patients	O
exhibited	O
elevated	O
interferon-alpha	B-CHEMICAL
levels	O
and	O
dysregulated	O
complement	B-PROCESS
activation	I-PROCESS
pathways.	O

The	O
anti-inflammatory	B-PROCESS
treatment	I-PROCESS
reduced	O
nuclear	B-PROCESS
factor-kappa	I-PROCESS
B	I-PROCESS
signaling	I-PROCESS
while	O
preserving	O
regulatory	B-PROCESS
T-cell	I-PROCESS
function.	I-PROCESS

Rheumatoid	B-DISEASE
arthritis	I-DISEASE
progression	O
involved	O
enhanced	O
matrix	B-CHEMICAL
metalloproteinase	I-CHEMICAL
expression	O
and	O
accelerated	O
cartilage	B-PROCESS
degradation	I-PROCESS
processes.	O

Sepsis	B-DISEASE
patients	O
demonstrated	O
increased	O
procalcitonin	B-CHEMICAL
biomarkers	O
and	O
impaired	O
neutrophil	B-PROCESS
antimicrobial	I-PROCESS
function.	O

The	O
immunomodulatory	B-PROCESS
therapy	I-PROCESS
restored	O
interleukin-10	B-PROCESS
production	I-PROCESS
while	O
reducing	O
pro-inflammatory	B-PROCESS
cytokine	I-PROCESS
storm	I-PROCESS
responses.	O

Multiple	B-DISEASE
sclerosis	I-DISEASE
patients	O
showed	O
enhanced	O
T-helper	B-PROCESS
17	I-PROCESS
cell	I-PROCESS
differentiation	I-PROCESS
and	O
disrupted	O
blood-brain	B-PROCESS
barrier	I-PROCESS
integrity.	I-PROCESS

Asthma	B-DISEASE
exacerbation	O
correlated	O
with	O
increased	B-PROCESS
eosinophil	I-PROCESS
recruitment	I-PROCESS
and	O
elevated	O
immunoglobulin	B-CHEMICAL
E	I-CHEMICAL
antibody	O
levels.	O

The	O
corticosteroid	B-CHEMICAL
treatment	O
suppressed	O
inflammatory	B-PROCESS
gene	I-PROCESS
transcription	I-PROCESS
through	O
glucocorticoid	B-PROCESS
receptor	I-PROCESS
activation	I-PROCESS
mechanisms.	O

